The filing is a routine insider intent-to-sell notice for a small position. Monitor for any acceleration of insider selling patterns or larger filings that could signal changing sentiment among management.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $60.81entry
- T+1 · 13d ago +8.01%α +6.36% · $65.68
- T+5 · 7d ago +9.13%α +9.71% · $66.36
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jim Wassil, an officer of Vaxcyte, filed a Form 144 notice of intent to sell 2,250 shares of common stock, with an approximate market value of $139,230. The shares are to be sold through UBS Financial Services on or after November 2, 2026, following the exercise of stock options. This is a relatively small sale relative to the company's $9.9B market cap and the officer's recent selling history, and is consistent with routine insider transactions for tax or diversification purposes.
Key Facts
- Jim Wassil, an officer of Vaxcyte, filed Form 144 to sell 2,250 shares of common stock.
- The proposed sale value is approximately $139,230 based on the filing date.
- The shares were acquired via exercise of stock options on November 2, 2026.
- The sale is to be executed through UBS Financial Services Inc.
- The filing shows Wassil has sold shares in multiple transactions from August to October 2026, totaling over $2.2M in prior sales.
- The proposed sale represents about 0.0014% of Vaxcyte's $9.9B market cap.
Financial Impact
Proposed sale of 2,250 shares valued at approximately $139,230, a de minimis amount relative to the company's $9.9B market cap.
Risk Factors
- Form 144 is only an intent to sell; the actual sale may not occur.
- The officer has a history of periodic option exercises and sales, so this is not an unusual pattern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001969223-26-001117 |
| Document: 0001969223-26-001117-index.html | 0001969223-26-001117 |
| Document: 0001969223-26-001117.txt | 0001969223-26-001117 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $63.37 +1.55% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $63.37 −2.04% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Viewing Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $63.37 +10.30% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $63.37 +11.22% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers